Scancell Holdings plc (SCP.F)

0,0890 -0,0040 (-4,30%) Börsenschluss: 03:08PM CEST

Scancell Holdings plc

Bellhouse Building
Unit 202 Sanders Road Oxford Science Park
Oxford OX4 4GD
United Kingdom
44 18 6558 2066
https://www.scancell.co.uk

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 51

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Prof. Lindy Gillian Durrant Ph.D.	Founder, CEO, Chief Scientific Officer & Director	432,62k	N/A	1957
Dr. Sally Elizabeth Adams	Executive Officer	297,12k	N/A	1961
Mr. Sathijeevan Nirmalananthan	CFO & Director	N/A	N/A	1986
Dr. Samantha Paston Ph.D.	Head of Translational Research	N/A	N/A	N/A
Dr. Adrian Parry Ph.D.	Head of Manufacturing	N/A	N/A	N/A
Dr. Mandeep Sehmi	Head of Business Development	N/A	N/A	N/A
Dr. Callum Scotthasbeen	Head of Development	N/A	N/A	N/A
Mr. Keith Charles Green	Company Secretary	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel immunotherapies and vaccines for the treatment of cancer and infectious disease. Its product candidates include SCIB1, an ImmunoBody cancer vaccine that is in Phase II for the treatment of metastatic melanoma; and SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumors, including non-small cell lung cancer. It also develops Modi-1, a citrullinated peptides vaccine that is in phase I/II clinical trials for the treatment of solid tumors including triple negative breast, ovarian, renal, and head and neck cancers; and Modi-2, which targets homocitrullinated cancer antigens. In addition, the company focuses to develop SCOV1 and SCOV2 COVIDITY, a DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.

Corporate Governance

Scancell Holdings plcs ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.